Intentional overdose of liraglutide in a non-diabetic patient causing severe hypoglycemia.
CJEM · 2018
Last updated 2026-05-28A non-diabetic person intentionally took too much liraglutide, a GLP-1 drug, and experienced severe low blood sugar. The patient needed hospital care, including a dextrose infusion and close monitoring in the intensive care unit. Prior reports did not link liraglutide overdose to hypoglycemia in diabetic patients.
AI summary of the abstract below.
| Journal | CJEM, 2018 |
|---|---|
| Citations | 12 |
| Relative citation ratio | 0.67 |
| NIH percentile | 37 |
| Molecules | liraglutide |
Abstract
ABSTRACTCases of liraglutide overdose are rare in the literature. Prior reports have not found hypoglycemia related to the medication overdose. We describe a case of a non-diabetic patient who intentionally overdosed on liraglutide leading to severe hypoglycemia. The patient required admission to the intensive care unit for a dextrose infusion and close monitoring. Glucagon-like protein-1 agonists are recognized for their safety and rarely causing hypoglycemia in diabetic patients. However, in this case the patient's non-diabetic status may have put him at risk for hypoglycemia in contrast to prior cases showing no hypoglycemia in diabetic patients. The case highlights the possible dangers of liraglutide overdose and need for blood glucose monitoring in the acute presentation.
Verbatim abstract via PubMed 29397808 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.